CD8A and neoplasm: These biomarkers mainly focus on characterizing unique features of pre-existing anti-tumor reactivity in the tumor microenvironment (TME) and include programmed death-ligand 1 (PD-L1) expression3, CD8+ T-cell infiltration11, T-cell repertoire clonality8, and panel-based immunological signatures12.